<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>11143501</identifier>
<setSpec>0213-4853</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Larrodé, P</dc:author>
<dc:author>Mayordomo, J I</dc:author>
<dc:author>Iñiguez, C</dc:author>
<dc:author>Mauri, J A</dc:author>
<dc:author>Trés, A</dc:author>
<dc:author>Morales, F</dc:author>
<dc:description xml:lang="en">Peripheral neurotoxicity is a crucial side effect of chemotherapeutic agents. It is the only situation where there is no preventive treatment. Neuromuscular toxicity has become the major dose limiting side effect for many chemotherapeutic agents. The iatrogenic toxic neuropathy is a growing neurologic problem, as cancer patients are beign treated with increasing doses of chemotherapy drugs. Major advances in cancer treatment have resulted from the use of drug combinations; for some combinations this raises the possibility of sinergistic neurotoxicity. The following report reviews the SNP toxicities encountered with cisplatin, vincristine, taxanes and others, and methods to minimize the deleterious effect of chemotherapeutic agents.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Oct </dc:date>
<dc:title xml:lang="es">Neurotoxicidad en el sistema nervioso periférico secundaria a tratamiento con quimioterapia.</dc:title>
<dc:title xml:lang="en">[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .</dc:title>
<dc:publisher>Neurologia (Barcelona, Spain)</dc:publisher>
</metadata>
</record>
</pubmed-document>
